Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-021-04017-2
Abstract: The effect of preoperative vedolizumab (VDZ) therapy on postoperative complications in inflammatory bowel disease (IBD) patients is still controversial. This meta-analysis aims to review postoperative complications of IBD patients who preoperatively received VDZ. A meta-analysis…
read more here.
Keywords:
vdz;
postoperative complications;
infectious complications;
ibd patients ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2021 at "Genomics"
DOI: 10.1016/j.ygeno.2021.04.011
Abstract: Infliximab/adalimumab (IFX/ADA) and vedolizumab (VDZ) are the most widely used biologics in inflammatory bowel diseases. Current models used to predict their efficacies are restricted to either Crohn's disease or ulcerative colitis or to only one…
read more here.
Keywords:
ifx ada;
vdz;
inflammatory bowel;
bowel diseases ... See more keywords
Photo by cdc from unsplash
Sign Up to like & get
recommendations!
1
Published in 2023 at "Scandinavian journal of gastroenterology"
DOI: 10.1080/00365521.2023.2176252
Abstract: OBJECTIVE Vedolizumab (VDZ) for subcutaneous (SC) administration has recently become available. We aimed to assess feasibility, safety and clinical outcome when switching from intravenous (IV) to SC VDZ maintenance treatment in a real world cohort…
read more here.
Keywords:
vdz;
disease;
maintenance treatment;
switching intravenous ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.392
Abstract: Anti-TNF agents and GSALT therapy (MAdCAM α4β7 blocker) are available treatment options for patients (pts) with moderate-to-severe CD. There are limited data on the optimal sequencing of these two mechanisms of action (MOAs) from the…
read more here.
Keywords:
vdz;
persistence;
anti tnf;
treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.414
Abstract: Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking monoclonal anti-a4β7-integrin antibody, has showed efficacy in multiple phase 3 clinical trials in patients (pts) with inflammatory bowel disease (IBD). Decreased likelihood of response to adalimumab was previously observed…
read more here.
Keywords:
vdz;
without asa;
efficacy;
concomitant asa ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.649
Abstract: Vedolizumab (VDZ) has demonstrated remission in ulcerative colitis (UC) and Crohn’s disease (CD), but its impact on patient (pt) fatigue is not well understood. Herein we report interim fatigue analysis data from a Belgian registry…
read more here.
Keywords:
colitis;
fatigue;
crohn;
vdz ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjac190.0741
Abstract: Vedolizumab (VDZ) is a gut-selective, anti- lymphocyte trafficking drug inhibiting α4β7-integrin approved for treatment of moderately to severely Crohn's disease (CD) and ulcerative colitis (UC). Medical charts from CD patients were retrospectively reviewed in sites…
read more here.
Keywords:
anti tnf;
vdz;
group;
treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Inflammatory Bowel Diseases"
DOI: 10.1097/01.mib.0000512530.93619.36
Abstract: Background: Vedolizumab (VDZ) is an anti-integrin biologic used in the treatment of ulcerative colitis (UC) and Crohn's disease (CD). In clinical trials, higher trough levels at weeks 6 and 52 were associated with higher rates…
read more here.
Keywords:
maintenance therapy;
vdz;
remission;
vdz levels ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "AIDS"
DOI: 10.1097/qad.0000000000002149
Abstract: OBJECTIVE The combined cART and anti-α4β7 RM-Act-1 antibody therapy allows macaques to durably control SIV rebound after withdrawal of the interventions. Here, we aimed to investigate whether vedolizumab (VDZ), a clinical-grade humanized anti-α4β7 antibody, would…
read more here.
Keywords:
vdz;
humanized mice;
cart;
rebound ... See more keywords